business
COMPANY BENCHMARKING • UNITED STATES

Novartis International Ag - Company Profile

Access all 5,000+ company profiles through Benchmarking Pro, available to Membership Plus subscribers. Unlock interactive competitor comparison tools that show you how Novartis International Ag stacks up to the competition and put relevant competitor and industry information at your fingertips.


Novartis International Ag - Overview

Brands
Advanced Accelerator Applications, Desenex, Famvir, Lamisil, Sandoz
Description
Novartis International Ag is a private company with an estimated 104,323 employees. In the US, the company has a notable market share in at least one industry: Cold Sore Medication Manufacturing, where they account for an estimated 11.4% of total industry revenue and are considered a Laggard because they display lower market share alongside slower profit and revenue growth than their peers.
Company Details

Registered Name: Novartis International Ag

Company Type: Other

Employees: 104323

Novartis International Ag - Operating Industries and Main Competitors

error_outline To view all of Novartis International Ag's operating industries and competitors, see purchase options.

Novartis International Ag - Products and Services

  • Cold Sore Medication Manufacturing

  • Of the 3 core revenue-generating products and services in the Cold Sore Medication Manufacturing industry, Novartis International Ag offers:
    • Oral prescription medications
    • OTC medications and generics
    • Topical prescription medications
error_outline To view Novartis International Ag's full products and services, see purchase options.

Novartis International Ag - Analyst Insights

Fourth highest selling innovative medicine brand Lucentis will lose its European patent in 2022

In 2020, Roche’s patent for macular degeneration drug Lucentis expired. Novartis, owning a significant portion of Roche, maintained revenue growth despite a 25% year over year drop in Q2 Lucentis sales. In 2021, the company reported a 12.0% increase in sales generated predominately from Europe and emerging markets. Lucentis’ European patent is set to expire in 2022. As the fourth highest selling brand in the innovative medicine division, Novartis may see significant declines in revenue over the next year. A biosimilar, or nearly identical product, from Samsung Bioepis received FDA approval in September 2021.

Competition|New Activity


In response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.

Lorem Ipsum text header Report Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.

Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.

error_outline To view all analyst insights on Novartis International Ag, see purchase options.

Novartis International Ag - SWOT Analysis

Strengths and weaknesses take into account internal factors, and are based on Novartis International Ag's performance in comparison to its competitors. Opportunities and Threats focus on external influences, and are based on trends and demand in the Cold Sore Medication Manufacturing industry.
Strengths
Days Receivables: x.x%
Purchase a membership to unlock the full SWOT analysis of this company.
lock
Rank: 2 of 3 peers
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Annual Turnover: x.x%
Purchase a membership to unlock the full SWOT analysis of this company.
lock
Rank: 2 of 3 peers
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Weaknesses
Credit Risk: x.x%
Purchase a membership to unlock the full SWOT analysis of this company.
lock
Rank: 2 of 3 peers
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Revenue per Employee: $xx
Purchase a membership to unlock the full SWOT analysis of this company.
lock
Rank: 2 of 3 peers
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Opportunities
  • AAAAA
  • AAAAA
  • AAAAA
Threats
  • AAAAA
  • AAAAA
  • AAAAA

error_outline To view Novartis International Ag's full SWOT analysis, see purchase options.

GET INSTANT ACCESS WITH MEMBERSHIP PLUS

100% Money Back Guarantee Digicert Trusted

BENCHMARKING PRO

What's Inside
Benchmarking Pro?

Available with US Membership Plus packages, this suite of company and industry data:

Benchmarks companies against industry averages or like-sized segments, as well as close competitors
Identifies real-world strengths, opportunites, weaknesses and threats
Reveals growth opportunities or red flags in a business growth strategy

Included in Report

  • Enterprise History & Synopsis
    Enterprise History & Synopsis
  • Enterprise Financial Statements
    Company Financial Statements
  • Financial Ratios
    Industry Market Share Breakdown
  • Industry Averages
    Industry Competitor Matrix
  • Competitive Landscape
    SWOT Analysis
  • Key Enterprise Personnel
    Products and Services
  • Subsidiaries & Ownership Structure
    Key Company Benchmarks

Why purchase access to Benchmarking Pro?

This profile on Novartis International Ag includes:

  • Company Overview
  • Company Revenue and Employee Data
  • Company Financial Statements
  • Industry Market Share Breakdown
  • Industry Competitor Matrix
  • SWOT Analysis
  • Products and Services
  • Key Company Benchmarks
  • Interconnected Competitor Profiles and Industry Reports
  • Full Access to Benchmarking Pro

The IBISWorld Benchmarking Pro solution enables you to:

  • Understand an enterprise’s competitive landscape and how they perform within a like-sized industry segment.
  • Benchmark companies against industry averages, segment averages and their competitors.
  • Identify real-world strengths, opportunities, weaknesses and threats for companies.
  • Target growth opportunities or spot red flags in a business growth strategy.
  • Toggle between company profiles and industry reports for a 360 degree view of a company's position.

IBISWorld provides profiles on thousands of leading companies around the world. Our clients rely on our information and data to stay up-to-date on business and industry trends across all sectors of the economy. This company profile, along with the corresponding competitor and industry data provided, includes thoroughly researched, reliable and current information that will help you to make faster, better business decisions.

Trusted by More Than 10,000 Clients Around the World

  • IBISWorld client - VISA
  • IBISWorld client - ADP
  • IBISWorld client - Deloitte
  • IBISWorld client - AMEX
  • IBISWorld client - Bank of Montreal